The Foundation Fighting Blindness Retinal Degeneration Fund sold 1,700,000 shares of Opus Genetics (NASDAQ:IRD) common stock, generating $7,394,999.
Shares were sold at $4.35 each. Currently trading at $4.45, the stock has declined 11.7% over the past week but posted a 347% return over the last year.
The fund's directors, Adrienne Graves and Jean Bennett, serve on Opus Genetics' board. The fund now holds 3,792,171 shares directly.
Opus Genetics recently reported positive gene therapy trial results, with over 30-fold improvements in cone sensitivity. The FDA accepted its LCA5 therapy into a rare disease program.
